Lilly CEO raises concerns about Novo-Catalent buy, calling the Novo Nordisk deal ‘unusual’

Eli Lil­ly has ex­pressed reser­va­tions about the No­vo-Catal­ent deal and its po­ten­tial im­pact on the wider man­u­fac­tur­ing in­dus­try.

“Giv­en the na­ture of this trans­ac­tion — a ver­ti­cal in­te­gra­tion where the client list of Catal­ent might num­ber in ex­cess of 100 en­ti­ties, all of which plan to com­pete in some way with No­vo Nordisk — it sets up for an in­ter­est­ing in­quiry by every­body [in­clud­ing] politi­cians,” CEO David Ricks said in an in­ter­view with the Fi­nan­cial Times.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.